… of FLT3 limits the therapeutic effects of these inhibitors. As in many other cases, it …
molecular dynamics (MD) simulations of FLT3 were carried out with an inhibited form (FLT-quizartinib …

… to the highly potent type II FLT3 inhibitor quizartinib (10), which … have suggested that the
molecular mechanism of TKI resistance … To elucidate the structural mechanism of resistance …

… assays to identify that quizartinib targets related class III RTKs… quizartinib treatment of
leukemic cells leads to inhibition of mutant KIT, PDGFR and FLT3 isoforms - with resultant inhibition …

… AML patients are not likely to benefit from a quizartinib/pexidartinib rotation protocol. A
combination of tyrosine kinase inhibitors (with different molecular targets) might be more useful in …

… These inhibitors, rather than being specifically designed to target FLT3, were developed …
FLT3 inhibitors other than quizartinib). Molecular insights into the mechanisms underlying these …

… The molecular formula of quizartinib is N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,
3]benzothiazol-2-yl]phenyl} urea dihydrochloride ( Figure 1 ). It …

… structure of quizartinib bound to FLT3 impedes efforts at improving FLT3 inhibitors. We now
… We had previously used modeling and molecular docking to predict how quizartinib binds to …

… Molecular targets have acquired a significant interest in the treatment of AML and are
changing … As a Type II inhibitor, quizartinib binds to the hydrophobic region adjacent to the ATP-…

… quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib,
compared with those of other FLT3 inhibitors. … kinases showed that quizartinib and AC886 …

… pathways, while Quizartinib can inhibit these downstream … is a deeper understanding in
molecular biology, immunology, … Quizartinib, a specific oral FLT3 inhibitor which can continue …